Esther Rajavelu - Feb 9, 2023 Form 4 Insider Report for Fulcrum Therapeutics, Inc. (FULC)

Role
Chief Financial Officer
Signature
/s/ Gregory Tourangeau, as attorney-in-fact for Esther Rajavelu
Stock symbol
FULC
Transactions as of
Feb 9, 2023
Transactions value $
$0
Form type
4
Date filed
2/13/2023, 03:15 PM
Previous filing
Jan 10, 2022
Next filing
Nov 15, 2023

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction FULC Stock Option (right to buy) Award $0 +160K $0.00 160K Feb 9, 2023 Common Stock 160K $12.59 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This option was granted on February 9, 2023 and is scheduled to vest in equal quarterly installments over four years beginning on the vesting commencement date of January 1, 2023, subject to the reporting person's continued service on each such vesting date.